DL-AP3
CAS No. : 5652-28-8
| Size | Price | Stock |
|---|---|---|
| 100mg | $308 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-100786 |
| M.Wt: | 169.07 |
| Formula: | C3H8NO5P |
| Purity: | >98 % |
| Solubility: | H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C) |
DL-AP3 is a competitive mGluR1 and mGluR5 antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect[1][2][3].
In Vitro: DL-AP3 (10 µM, 6 h) alleviates oxygen-glucose deprivation (OGD)-induced injury (cell viability) in primary neurons[1].
DL-AP3 (10 µM, 6 h) recovers the decreased levels of p-Akt1 and the increase of cytochrome C induced by OGD in primary neurons[1].
DL-AP3 (1-100 µM) inhibits activity of rat brain phosphoserine phosphatase, with an IC50 of 187 µM and Ki of 77 µM[2].
DL-AP3 (10 μM, 10 min) together with SKF81297 (5 μM) induces a significant Long-term potentiation (LTP) in the slices of Fmr1 KO mice[3].
In Vivo: DL-AP3 (4 mg/kg, i.p., for 5 weeks) with SKF81297 (1 mg/kg, i.p.) reduces the hyperactivity phenotype in Fmr1 KO mice[3].
DL-AP3 (4.0-12.0 mg/animal, i.c.v. infusion, 100 μL) blocks development of visceral pain symptoms and neuroendocrinological changes in the blood plasma of sheep[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- DL-AP3
- Cat. No.:
- HY-100786
- Quantity:
Your information is safe with us.